Regeneron Pharmaceuticals, Inc.
REGENERON PHARMACEUTICALS INC (Form: 4, Received: 12/28/2005 17:24:42)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GOLDBERG MURRAY A
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS INC [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP Fin & Admin, CFO, & Treas
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER RD
3. Date of Earliest Transaction (MM/DD/YYYY)

12/23/2005
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   12/23/2005     M/K (1)    1000   A $12.750   37516   D    
Common Stock   12/23/2005     S/K (1)    1000   D $12.990   36516   D    
Common Stock   12/23/2005     M/K (1)    1000   A $12.750   37516   D    
Common Stock   12/23/2005     S/K (1)    1000   D $13.000   36516   D    
Common Stock   12/23/2005     M/K (1)    1000   A $12.750   37516   D    
Common Stock   12/23/2005     S/K (1)    1000   D $13.050   36516   D    
Common Stock   12/23/2005     M/K (1)    100   A $12.750   36616   D    
Common Stock   12/23/2005     S/K (1)    100   D $13.080   36516   D    
Common Stock   12/23/2005     M/K (1)    700   A $12.750   37216   D    
Common Stock   12/23/2005     S/K (1)    700   D $13.090   36516   D    
Common Stock   12/23/2005     M/K (1)    4200   A $12.750   40716   D    
Common Stock   12/23/2005     S/K (1)    4200   D $13.100   36516   D    
Common Stock   12/23/2005     M/K (1)    1804   A $12.750   38320   D    
Common Stock   12/23/2005     S/K (1)    1804   D $13.110   36516   D    
Common Stock   12/23/2005     M/K (1)    1100   A $12.750   37616   D    
Common Stock   12/23/2005     S/K (1)    1100   D $13.120   36516   D    
Common Stock   12/23/2005     M/K (1)    246   A $12.750   36762   D    
Common Stock   12/23/2005     S/K (1)    246   D $13.130   36516   D    
Common Stock   12/23/2005     M/K (1)    1000   A $12.750   37516   D    
Common Stock   12/23/2005     S/K (1)    1000   D $13.160   36516   D    
Common Stock   12/23/2005     M/K (1)    17850   A $12.750   54366   D    
Common Stock   12/23/2005     F/K (1)    17098   D $13.310   37268   D    
Common Stock   12/23/2005     F/K (1)    260   D $13.310   37008   D    
Common Stock   12/27/2005     S/K (1)    492   D $14.94   36516   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       1000      (2) 1/2/2006   Common Stock   1000   $0.00   11150   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       1000      (2) 1/2/2006   Common Stock   1000   $0.00   10150   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       1000      (2) 1/2/2006   Common Stock   1000   $0.00   9150   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       100      (2) 1/2/2006   Common Stock   100   $0.00   9050   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       700      (2) 1/2/2006   Common Stock   700   $0.00   8350   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       4200      (2) 1/2/2006   Common Stock   4200   $0.00   4150   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       1804      (2) 1/2/2006   Common Stock   1804   $0.00   2346   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       1100      (2) 1/2/2006   Common Stock   1100   $0.00   1246   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       246      (2) 1/2/2006   Common Stock   246   $0.00   1000   D    
Incentive Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       1000      (2) 1/2/2006   Common Stock   1000   $0.00   0   D    
Non-Qualified Stock Option (right to buy)   $12.750   12/23/2005     M/K  (1)       17850      (2) 1/2/2006   Common Stock   17850   $0.00   0   D    

Explanation of Responses:
( 1)  Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
( 2)  Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GOLDBERG MURRAY A
777 OLD SAW MILL RIVER RD
TARRYTOWN, NY 10591


SVP Fin & Admin, CFO, & Treas

Signatures
By: /s/ **Stuart Kolinski For: /s/ **Murray A. Goldberg 12/28/2005
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

POWER OF ATTORNEY

Know all by these presents,
that the undersigned hereby constitutes and appoints each of Leonard
Schleifer, , Beverly Dubs, Stuart Kolinski, Murray Goldberg, and Douglas
McCorkle signing singly, the undersigned's true and lawful

attorney-in-fact to:

(1) execute for and on behalf of the undersigned in the undersigned's capacity as a director of Regeneron Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-act on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with
full power of substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such
attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this
power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving
in such capacity at the request of the undersigned, are not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the

undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS
WHEREOF, the undersigned has caused this Power of Attorney to be executed
as of this 12th day of September, 2005.

                                                                **/s/Murray A.
Goldberg
                                                                -----------------------
                                                                Signature

Murray A. Goldberg
Print
Name

Page 1